Valneva Austria GmbH
50
0
3
39
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
8.0%
4 terminated/withdrawn out of 50 trials
90.7%
+4.2% vs industry average
48%
24 trials in Phase 3/4
54%
21 of 39 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (50)
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
Role: lead
VLA1553-403 Pregnancy Surveillance Study
Role: lead
Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
Role: lead
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
Role: lead
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
Role: lead
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
Role: lead
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
Role: lead
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
Role: collaborator
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
Role: collaborator
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
Role: lead
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
Role: lead
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
Role: collaborator
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
Role: lead
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
Role: lead
Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
Role: lead
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
Role: lead
Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years
Role: lead
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
Role: lead
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
Role: lead
Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
Role: collaborator